Yarrow Bioscience Return on Equity

Yarrow Bioscience (YARW) currently reports a ROE of -151935.89%. That is below the Healthcare sector average of -75.84%. Use the charts on this page to explore Yarrow Bioscience's ROE history and peer comparisons.

Yarrow Bioscience's ROE of -151935.89% is lower than the Healthcare sector average of -75.84%. That is roughly 200249.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Yarrow Bioscience's current -151935.89% should be judged against Healthcare norms (sector average: -75.84%) and against YARW's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -151935.89%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.84%. From there, open related valuation or income-statement pages for Yarrow Bioscience, and consider following YARW for alerts when major investors trade the stock.

Yarrow Bioscience is classified in the Healthcare sector. On ROE, it currently shows -151935.89% versus a sector average near -75.84%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing YARW with unrelated industries.